Emerging role of MicroRNAs in drug-resistant breast cancer

Gene Expression

Volumn 15, Issue 3, 2011, Pages 141-151

  Majumder, Sarmila ^a   Jacob, Samson T ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Drug resistance; MicroRNAs

Indexed keywords

EXEMESTANE; FULVESTRANT; MEGESTROL; MICRORNA; MICRORNA 106A; MICRORNA 10A; MICRORNA 126; MICRORNA 127; MICRORNA 146A; MICRORNA 15A; MICRORNA 16; MICRORNA 181; MICRORNA 181B; MICRORNA 200A; MICRORNA 200C; MICRORNA 206; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 23B; MICRORNA 26A; MICRORNA 26B; MICRORNA 27B; MICRORNA 301; MICRORNA 342; MICRORNA 345; MICRORNA 451; MICRORNA 489; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; APOPTOSIS; BIOGENESIS; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; GENE CONTROL; GENE EXPRESSION; GENETIC VARIABILITY; HORMONAL THERAPY; LONG TERM CARE; LYMPH NODE METASTASIS; METASTASIS; POSTMENOPAUSE; PREMEDICATION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR RECURRENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS;

EID: 81055145530     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221611X13176664479287     Document Type: Review

References (91)

1. Abolhoda, A.; Wilson, A. E.; Ross, H.; Danenberg, P. V.; Burt, M.; Scotto, K. W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5:3352-3356; 1999.
2. Aitken, A. 14-3-3 proteins on the MAP. Trends Biochem. Sci. 20:95-97; 1995.
3. Alexander, J. J.; Hauswirth, W. W. Adeno-associated viral vectors and the retina. Adv. Exp. Med. Biol. 613: 121-128; 2008.
4. Ambros, V. The functions of animal microRNAs. Nature 431:350-355; 2004.
5. Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297; 2004.
6. Bartel, D. P. MicroRNAs: Target recognition and regulatory functions. Cell 136:215-233; 2009.
7. Bergamaschi, A.; Katzenellenbogen, B. S. Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene; in press.
8. Blain, S. W.; Massague, I. Breast cancer banishes p27 from nucleus. Nat. Med. 8:1076-1078; 2002.
9. Bohnsack, M. T.; Czaplinski, K.; Gorlich, D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-mIRNAs. RNA 10:185-191; 2004.
10. Bonnefoi, H.; Underhill, C.; Iggo, R.; Cameron, D. Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic? Eur. J. Cancer 45:1733-1743; 2009.
11. Brabletz, S.; Brabletz, T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep. 11:670-677; 2010.
12. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:582-589; 2008.
13. Butta, A.; MacLennan, K.; Flanders, K. C.; Sacks, N. P.; Smith, I.; McKinna, A.; Dowsett, M.; Wakefield, L. M.; Sporn, M. B.; Baum, M.; et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:4261-4264; 1992.
14. Chatterjee, S.; Li, W.; Wong, C. A.; Fisher-Adams, G.; Lu, D.; Guha, M.; Macer, J. A.; Forman, S. J.; Wong, Jr., K. K. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 93:1882-1894; 1999.
15. Chaudhary, P. M.; Roninson, I. B. Induction of multi-drug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85:632-639; 1993.
16. Chendrimada, T. P.; Gregory, R. I.; Kumaraswamy, E.; Norman, J.; Cooch, N.; Nishikura, K.; Shiekhattar, R. TRBP recruits the Dicer complex to Ago2 for micro-RNA processing and gene silencing. Nature 436:740-744; 2005.
17. Chin, K. V.; Chauhan, S. S.; Pastan, I.; Gottesman, M. M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1: 361-365; 1990.
18. Chin, K. V.; Tanaka, S.; Darlington, G.; Pastan, I.; Gottesman, M. M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265: 221-226; 1990.
19. Chung, K. H.; Hart, C. C.; Al-Bassam, S.; Avery, A.; Taylor, J.; Patel, P. D.; Vojtek, A. B.; Turner, D. L. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res. 34:e53; 2006.
20. Cittelly, D. M.; Das, P. M.; Salvo, V. A.; Fonseca, J. P.; Burow, M. E.; Jones, F. E. Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31:2049-2057; 2010.
21. Cittelly, D. M.; Das, P. M.; Spoelstra, N. S.; Edgerton, S. M.; Richer, J. K.; Thor, A. D.; Jones, F. E. Down-regulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 9:317; 2010.
22. Colletti, R. B.; Roberts, J. D.; Devlin, J. T.; Copeland, K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 49:1882-1884; 1989.
23. Dunn, C.; Keam, S. J. Letrozole: A pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics 24:495-517; 2006.
24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717; 2005.
25. Ebert, M. S.; Neilson, J. R.; Sharp, P. A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4:721-726; 2007.
26. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H. F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E. M.; Kauppinen, S. LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899; 2008.
27. Elmen, J.; Thonberg, H.; Ljungberg, K.; Frieden, M.; Westergaard, M.; Xu, Y.; Wabren, B.; Liang, Z.; Orum, H.; Koch, T.; Wahlestedt, C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33:439-447; 2005.
28. Esau, C.; Kang, X.; Peralta, E.; Hanson, E.; Marcusson, E. G.; Ravichandran, L. V.; Sun, Y.; Koo, S.; Perera, R. J.; Jain, R.; Dean, N. M.; Freier, S. M.; Bennett, C. F.; Lollo, B.; Griffey, R. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem. 279: 52361-52365; 2004.
29. Frasor, J.; Chang, E. C.; Komm, B.; Lin, C. Y.; Vega, V. B.; Liu, E. T.; Miller, L. D.; Smeds, J.; Bergh, J.; Katzenellenbogen, B. S. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 66:7334-7340; 2006.
30. Galardi, S.; Mercatelli, N.; Giorda, E.; Massalini, S.; Frajese, G. V.; Ciafre, S. A.; Farace, M. G. miR-221 and rniR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kipl. J. Biol. Chem. 282:23716-23724; 2007.
31. Gillies, J. K.; Lorimer, I. A. Regulation of p27Kipl by miRNA 221/222 in glioblastoma. Cell Cycle 6:2005- 2009; 2007.
32. Gottesman, M. M.; Ling, V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett. 580:998-1009; 2006.
33. Greene, S. B.; Herschkowitz, J. I.; Rosen, J. M. Small players with big roles: MicroRNAs as targets to inhibit breast cancer progression. Curr. Drug Targets 11: 1059-1073; 2010.
34. Gregory, P. A.; Bert, A. G.; Paterson, E. L.; Barry, S. C.; Tsykin, A.; Farshid, G.; Vadas, M. A.; Khew-Goodall, Y.; Goodall, G. J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10:593-601; 2008.
35. Gupta, P. B.; Fillmore, C. M.; Jiang, G.; Shapira, S. D.; Tao, K.; Kuperwasser, C.; Lander, E. S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146:633-644; 2011.
36. Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404:293-296; 2000.
37. Harris, J. R.; Morrow, M.; Bonadonna, G.; Valadi, H., editors. Cancer of the breast. Philadelphia: Lippincott; 1993.
38. Hu, Z.; Jin, S.; Scotto, K. W. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Spl. J. Biol. Chem. 275:2979-2985; 2000.
39. Hutvagner, G.; Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297: 2056-2060; 2002.
40. lorio, M. V.; Ferracin, M.; Liu, C. G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J. P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G. A.; Querzoli, P.; Negrini, M.; Croce, C. M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065-7070; 2005.
41. Johnston, S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br. J. Cancer 90(Suppl. 1):S15-18; 2004.
42. Jordan, V. C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat. 31: 41-52; 1994.
43. Knabbe, C.; Lippman, M. E.; Wakefield, L. M.; Flanders, K. C.; Kasid, A.; Derynck, R.; Dickson, R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428; 1987.
44. Kong, W.; He, L.; Coppola, M.; Guo, J.; Esposito, N. N.; Coppola, D.; Cheng, J. Q. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 285: 17869-17879; 2010.
45. Korpal, M.; Lee, E. S.; Hu, G.; Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283:14910-14914; 2008.
46. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017; 2009.
47. Kovalchuk, O.; Filkowski, J.; Meservy, J.; Ilnytskyy, Y.; Tryndyak, V. P.; Chekhun, V. F.; Pogribny, I. P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7:2152-2159; 2008.
48. Kozomara, A.; Griffiths-Jones, S. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152-157; 2011.
49. Lacerda, L.; Pusztai, L.; Woodward, W. A. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist. Updat. 13:99-108;
50. Landthaler, M.; Yalcin, A.; Tuschl, T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr. Biol. 14:2162-2167; 2004.
51. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; Kim, V. N. The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415-419; 2003.
52. Lee, Y.; Kim, M.; Han, J.; Yeom, K. H.; Lee, S.; Back, S. H.; Kim, V. N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23:4051-4060; 2004.
53. Leonard, G. D.; Fojo, T.; Bates, S. E. The role of ABC transporters in clinical practice. Oncologist 8:411-424; 2003.
54. le Sage, C.; Nagel, R.; Egan, D. A.; Schrier, M.; Mesman, E.; Mangiola, A.; Anile, C.; Maira, G.; Mercatelli, N.; Ciafre, S. A.; Farace, M. G.; Agami, R. Regulation of the p27(Kipl) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26: 3699-3708; 2007.
55. Lewis, J. S.; Jordan, V. C. Selective estrogen receptor modulators (SERM5): Mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591:247-263; 2005.
56. Liang, Z.; Wu, H.; Reddy, S.; Zhu, A.; Wang, S.; Blevins, D.; Yoon, Y.; Zhang, Y.; Shim, H. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem. Biophys. Res. Commun. 363:542-546; 2007.
57. Lim, L. P.; Lau, N. C.; Garrett-Engele, P.; Grimson, A.; Schelter, J. M.; Castle, J.; Bartel, D. P.; Linsley, P. S.; Johnson, J. M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769-773; 2005.
58. Lonning, P. E. Molecular basis for therapy resistance. Mol. Oncol. 4:284-300; 2010.
59. Maillot, G.; Lacroix-Triki, M.; Pierredon, S.; Gratadou, L.; Schmidt, S.; Benes, V.; Roche, H.; Dalenc, F.; Auboeuf, D.; Millevoi, S.; Vagner, S. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res. 69:8332-8340; 2009.
60. Mani, S. A.; Guo, W.; Liao, M. J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715; 2008.
61. Martinez, J.; Patkaniowska, A.; Urlaub, H.; Luhrmann, R.; Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563-574; 2002.
62. Masri, S.; Liu, Z.; Phung, S.; Wang, E.; Yuan, Y. C.; Chen, S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res. Treat. 124:89-99; 2010.
63. Medina, R.; Zaidi, S. K.; Liu, C. G.; Stein, J. L.; van Wijnen, A. J.; Croce, C. M.; Stein, G. S. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 68:2773-2780; 2008.
64. Miller, T. E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C. L.; Jacob, S.; Majumder, S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kipl. J. Biol. Chem. 283:29897-29903; 2008.
65. Mitra, D.; Brumlik, M. J.; Okamgba, S. U.; Zhu, Y.; Duplessis, T. T.; Parvani, J. G.; Lesko, S. M.; Brogi, E.; Jones, F. E. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8:2152-2162; 2009.
66. Morel, A. P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3:e2888; 2008.
67. Musgrove, E. A.; Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9:631-643; 2009.
68. Naresh, A.; Thor, A. D.; Edgerton, S. M.; Torkko, K. C.; Kumar, R.; Jones, F. E. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 68:6387-6395; 2008.
69. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194:23-28; 1976.
70. Obad, S.; dos Santos, C. O.; Petri, A.; Heidenblad, M.; Broom, O.; Ruse, C.; Fu, C.; Lindow, M.; Stenvang, J.; Straarup, E. M.; Hansen, H. F.; Koch, T.; Pappin, D.; Hannon, G. J.; Kauppinen, S. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43:371-378; 2011.
71. Osborne, C. K.; Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62:233-247; 2011.
72. Park, S. M.; Gaur, A. B.; Lengyel, E.; Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894-907; 2008.
73. Pogribny, I. P.; Filkowski, J. N.; Tryndyak, V. P.; Golubov, A.; Shpyleva, S. I.; Kovalchuk, O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 127:1785-1794; 2010.
74. Pusztai, L.; Hortobagyi, G. N. High-dose chemotherapy: How resistant is breast cancer? Drug Resist. Updat. 1: 62-72; 1998.
75. Rao, X.; Di Leva, G.; Li, M.; Fang, K; Devlin, C.; Hartman-Frey, C.; Burow, M. E.; Ivan, M.; Croce, C. M.; Nephew, K. P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30:1082-1097; 2010.
76. Rodriguez, A.; Griffiths-.Tones, S.; Ashurst, J. L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 14:1902-1910; 2004.
77. Sayed, D.; Rane, S.; Lypowy, I.; He, M.; Chen, I. Y.; Vashistha, H.; Yan, L.; Malhotra, A.; Vatner, D.; Abdellatif, M. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19: 3272-3282; 2008.
78. Scherr, M.; Venturini, L.; Battmer, K.; Schaller-Schoenitz, M.; Schaefer, D.; Dallmann, I.; Ganser, A.; Eder, M. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 35:e149; 2007.
79. Shi, W.; Gerster, K.; Alajez, N. M.; Tsang, J.; Waldron, L.; Pintilie, M.; Hui, A. B.; Sykes, J.; P'ng, C.; Miller, N.; McCready, D.; Fyles, A.; Liu, F. F. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 71:2926-2937; 2011.
80. Shimono, Y.; Zabala, M.; Cho, R. W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S. P.; Chiao, E.; Dirbas, F. M.; Somlo, G.; Pera, R. A.; Lao, K.; Clarke, M. F. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592-603; 2009.
81. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D. H.; Gainche, L.; Sena-Esteves, M.; Curry, Jr., W. T.; Carter, B. S.; Krichevsky, A. M.; Breakefield, X. O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10:1470-1476; 2008.
82. Thiery, J. P.; Acloque, H.; Huang, R. Y.; Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890; 2009.
83. Tzivion, G.; Avruch, J. 14-3-3 proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation. J. Biol. Chem. 277:3061-3064; 2002.
84. Uchiumi, T.; Kohno, K.; Tanimura, H.; Matsuo, K.; Sato, S.; Uchida, Y.; Kuwano, M. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ. 4: 147-157; 1993.
85. Uhr, J. W.; Scheuermann, R. H.; Street, N. E.; Vitetta, E. S. Cancer dormancy: Opportunities for new therapeutic approaches. Nat. Med. 3:505-509; 1997.
86. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J. J.; Lotvall, J. O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:654- 659; 2007.
87. Wellner, U.; Schubert, J.; Burk, U. C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V. G.; Morton, J.; Sansom, O.; Schuler, J.; Stemmler, M. P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11:1487-1495; 2009.
88. Wright, J. A.; Richer, J. K.; Goodall, G. J. microRNAs and EMT in mammary cells and breast cancer. J. Mammary Gland Biol. Neoplasia 15:213-223; 2010.
89. Xin, F.; Li, M.; Balch, C.; Thomson, M.; Fan, M.; Liu, Y.; Hammond, S. M.; Kim, S.; Nephew, K. P. Computational analysis of microRNA profiles and theft target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25:430-434; 2009.
90. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123; 2007.
91. Zhao, J. J.; Lin, J.; Yang, H.; Kong, W.; He, L.; Ma, X.; Coppola, D.; Cheng, J. Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079-31086; 2008.